Redmile Group LLC increased its stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 14.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,097,220 shares of the company’s stock after buying an additional 400,572 shares during the quarter. Pliant Therapeutics comprises approximately 1.7% of Redmile Group LLC’s investment portfolio, making the stock its 22nd biggest position. Redmile Group LLC owned about 5.13% of Pliant Therapeutics worth $46,149,000 as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of the stock. Price T Rowe Associates Inc. MD increased its position in Pliant Therapeutics by 4.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,959,088 shares of the company’s stock worth $58,991,000 after purchasing an additional 173,172 shares in the last quarter. Capital International Investors grew its stake in Pliant Therapeutics by 50.9% during the first quarter. Capital International Investors now owns 1,377,327 shares of the company’s stock worth $20,522,000 after purchasing an additional 464,860 shares during the period. EntryPoint Capital LLC increased its stake in shares of Pliant Therapeutics by 99.8% in the 1st quarter. EntryPoint Capital LLC now owns 20,006 shares of the company’s stock valued at $298,000 after acquiring an additional 9,992 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Pliant Therapeutics by 13.5% during the first quarter. Vanguard Group Inc. now owns 3,478,355 shares of the company’s stock valued at $51,827,000 after purchasing an additional 412,486 shares during the period. Finally, ProShare Advisors LLC raised its stake in Pliant Therapeutics by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 14,489 shares of the company’s stock worth $216,000 after buying an additional 1,203 shares during the period. Institutional investors own 97.30% of the company’s stock.
Insider Transactions at Pliant Therapeutics
In other Pliant Therapeutics news, General Counsel Mike Ouimette sold 7,656 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $11.56, for a total value of $88,503.36. Following the completion of the sale, the general counsel now owns 94,044 shares in the company, valued at $1,087,148.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Pliant Therapeutics news, General Counsel Mike Ouimette sold 7,656 shares of the stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $11.56, for a total transaction of $88,503.36. Following the completion of the sale, the general counsel now owns 94,044 shares of the company’s stock, valued at approximately $1,087,148.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bernard Coulie sold 38,710 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $11.56, for a total value of $447,487.60. Following the completion of the sale, the chief executive officer now owns 482,936 shares of the company’s stock, valued at approximately $5,582,740.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,596 shares of company stock worth $804,530. 6.40% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on Pliant Therapeutics
Pliant Therapeutics Price Performance
Pliant Therapeutics stock traded up $0.51 during trading on Monday, hitting $13.88. The stock had a trading volume of 1,805,491 shares, compared to its average volume of 483,451. The stock’s 50 day moving average is $11.96 and its two-hundred day moving average is $14.09. Pliant Therapeutics, Inc. has a 1 year low of $10.29 and a 1 year high of $20.23. The company has a debt-to-equity ratio of 0.07, a current ratio of 16.12 and a quick ratio of 16.12.
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) last released its quarterly earnings data on Monday, May 6th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.02). Analysts predict that Pliant Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.
About Pliant Therapeutics
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
Further Reading
- Five stocks we like better than Pliant Therapeutics
- What Does a Stock Split Mean?
- Survey: Top 175 Fittest Retirement Locations in America
- Energy and Oil Stocks Explained
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- The Significance of Brokerage Rankings in Stock Selection
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.